(BERLIN, Germany and LONDON, England) 22nd October 2018 - Aladdin Blockchain Technologies SE ("Aladdin"), a cutting-edge technology leader developing a new digital healthcare ecosystem that will revolutionise how members manage day-to-day healthcare, today announced they have entered into a non-legally binding memorandum of understanding with the Norwegian Centre on Healthy Ageing (NO-Age). As a result of this, an exciting partnership for research and development between Aladdin and NO-Age is under discussion.
The Norwegian Centre on Healthy Ageing (NO-Age) is a Norwegian integrated, interdisciplinary centre for human ageing research at international top level, with a translational goal to empower people to live longer, healthier, and more meaningful lives.
Taking advantage of the strong inter-disciplinary anti-ageing research expertise and translational resources of NO-Age, in conjunction with the leading successful experience of Aladdin in the fields of artificial intelligence (AI) and machine learning (ML), as well as in the production and marketing of clinical products, this collaboration will bring positive health outcomes to people who have ageing related chronic diseases, such as Alzheimer's disease, cardiovascular diseases and diabetes.
No-Age intends to use Aladdin's strength in AI and ML to advance biomedical research and biomedical commercialisation. No-Age and Aladdin will work closely in predictive analytics, clinical trials and drug discovery. Aladdin and NO-Age will use the extensive healthcare data available to NO-Age and develop an array of ML and AI toolkits to assist and accelerate research and study on age-related chronic diseases.
The current discussion about the first stage cooperation between Aladdin and NO-Age is anchored in NO-Age primary teams located at the University of Oslo (Norway), with the involvement of leading antiageing researchers from The University of Oxford (UK), The National Institute on Ageing (USA), Stanford University (USA), and Sun Yatsen University (China). Aladdin also plans to have further cooperation with other research parties in NO-Age.
This prospective partnership will enable NO-Age and Aladdin to explore the opportunities for AI and ML to accelerate medical advances from biomedical research. Aladdin expects to deliver an array of best-in-class machine learning and AI toolkits for clinical trial and drug discovery.
Wade Menpes-Smith (Chairman)
NO-Age website: www.noage100.com
About Aladdin Blockchain Technologies SE
Aladdin Blockchain Technologies SE (and its wholly owned subsidiary Aladdin Blockchain Technologies Ltd.) is a cutting-edge technology company leveraging blockchain, artificial intelligence and machine-learning techniques to revolutionise how day-to-day healthcare is managed. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather large sets of health and lifestyle data. These datasets are then analysed and used to reduce costs and improve the efficiency of healthcare treatments. Aladdin's analyses can identify trends related to chronic diseases, thus empowering patients by providing insight into the various elements affecting their health, while improving outcomes and overall access to healthcare. Aladdin's vision is to move toward an era of more efficient healthcare management and realize their purpose of improving global health outcomes.
End of Media Release
Issuer: Aladdin Blockchain Technologies Holding SE
Key word(s): Health
23.10.2018 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Aladdin Blockchain Technologies Holding SE
Unter den Linden 10
10117 Berlin
Germany
Phone: 030 700140449
E-mail: info@aladdinid.com
Internet: www.aladdinid.com
ISIN: DE000A12ULL2
WKN: A12ULL
Listed: Regulated Market in Dusseldorf
End of News DGAP Media© 2018 Dow Jones News
